As shown by previous studies, rosiglitazone, another antidiabetic drug in the thiazolidinedione class that has been shown to counteract TS‐induced down‐regulation of Nrf2,66 is a peroxisome proliferator‐activated receptor‐gamma (PPAR‐gamma) agonist. This evidence concerns the gene PPARG and Timothy syndrome.